To evaluate the in vivo safety and efficacy of a skin care formulation in terms of reduction in hyper pigmentation that is a acne PIH and sebum on healthy human participants - Nil

LOTUS HERBALS PVT LTD0 个研究点目标入组 30 人开始时间: 2026年7月20日最近更新: 2026年8月3日

试验速览

暂无简介。

•1.Being pregnant or breastfeeding or having 2.stopped breastfeeding within the past three months
•3.Refusing to provide assent by not signing the informed consent form
•4.Taking part in another study that may interfere with this study
•5.Being insulin dependent diabetic or non insulin dependent diabetic with recent therapy within the past six months
•6.Having progressive asthma either under treatment or with an asthma attack within the past two years
•7.Having a chronic skin disease that may modify skin reactivity in the test area except in studies specifically conducted on that skin disease
•8.Having unstable thyroid disease requiring treatment that has not been stable for at least six months
•9.Being diagnosed with epilepsy
•10.Receiving chronic medicinal treatment including aspirin based products anti inflammatory drugs antihistamines or corticosteroids administered by either general or local routes The only permitted medication is paracetamol
•11.Having skin hypersensitivity
•12.Having a diagnosed or highly probable allergy to one or more ingredients of the cosmetic products
•13.Having undergone surgery requiring general anesthesia for more than one hour within the past six months

发起方

LOTUS HERBALS PVT LTD